Skip to content
Screener

ImmunityBio, Inc. IBRX Reportable Segment — Total Revenue

Similar metrics at other companies

DocuSign logo
DOCUReportable Segment — Total Revenue
$830.24M+8.7%
Guidewire Software logo
GWREReportable Segment — Total Revenue
$372.54M+26.9%
UiPath logo
PATHReportable Segment — Total Revenue
$418.38M+17.3%
Andersen Group logo
ANDGReportable Segment — Total Revenue
$240.75M+15.7%
Lemonade logo
LMNDReportable Segment — Total Revenue
$258M+70.6%
DraftKings Inc. logo
DKNGReportable Segment — Total Revenue
$1.65B+16.8%

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.68B+242%
Enterprise value$7.92B+227%
P/S54.5×+14.8×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 7:37 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001326110-26-000059
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Total revenue$44,206$16,517
Cost of sales23858
Gross profit43,96816,459
Operating expenses
External research and development expense (including amounts with related parties) (1)20,0825,511
Internal research and development expense (including amounts with related parties): (2)
Personnel-related costs25,85023,065
Equipment, depreciation, and facility costs13,58813,192

ITEM 1. FINANCIAL STATEMENTS.

FAQ

What is ImmunityBio, Inc.'s reportable segment — total revenue?
ImmunityBio, Inc. (IBRX) reported reportable segment — total revenue of $44.21M in Q1 2026.
How has ImmunityBio, Inc.'s reportable segment — total revenue changed year-over-year?
ImmunityBio, Inc.'s reportable segment — total revenue increased by 167.6% year-over-year, from $16.52M to $44.21M.
What is the long-term trend for ImmunityBio, Inc.'s reportable segment — total revenue?
Over 3 years (2022 to 2025), ImmunityBio, Inc.'s reportable segment — total revenue has grown at a 678.6% compound annual growth rate (CAGR), from $240K to $113.29M.
What does reportable segment — total revenue mean?
Represents the total gross income generated by the specific business segment through its primary operations. This figure reflects the market demand for the segment's products or services before accounting for any associated costs.

Ask your AI about ImmunityBio, Inc.'s reportable segment — total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude